Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Match Group

Olaplex Holdings

RingCentral

Block

Some of the stocks that have suffered the most this year could get hit some more as investors sell them to create tax losses.

Block, RingCentral, and Other Stocks Facing Tax-Loss Selling

Baxter Reports Third-Quarter 2022 Results

Baxter International has had a rough year or so, with shares declining far more than the market has. Some of this was justified by the company's high share price and weakening fundamentals.

Baxter International: Despite Weakening On The Bottom Line, Shares Look Attractive

Baxter's (BAX) third-quarter results are likely to reflect growth in its Medication Delivery and Advanced Surgery businesses. Hillrom's products are likely to have boosted sales.

Baxter (BAX) to Report Q3 Earnings: Is a Beat in the Cards?

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for

Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.

3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio

Aptiv

Coca-Cola European Partners plc

Cigna

DXC Technology

Fiserv

Global Payments

McKesson

Tenet Healthcare

US Foods Holding

Larry Robbins is the founder and CEO of Glenview Capital Management, which is a New York-based hedge fund.

These Are The Top 10 Holdings Of Larry Robbins

DEERFIELD, Ill.--(BUSINESS WIRE)--The Baxter International Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), announced today it will provide a combined $3 million in new racial justice grants in 2022 to multiple organizations working in the United States. The funding aligns with Baxter's ACT: Activating Change Today program, a global multidimensional and multiyear initiative to advance racial justice within the workplace and within the communities and markets the compan

The Baxter International Foundation Announces $3 Million in New Grants to Organizations Working to Advance Racial Justice

Baxter stock (NYSE: BAX) has seen a 32% fall this year, underperforming the broader S&P500 index, down 17%.

Should You Buy Baxter Stock Under $60?

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2022 financial results on Thursday, October 27, 2022 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.c

Baxter to Host Third-Quarter 2022 Financial Results Conference Call for Investors

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reinforced its commitment to expand the pipeline of Black healthcare professionals through several programs that support Black students pursuing health and science degrees at Historically Black Colleges and Universities (HBCUs). For the 2022-2023 calendar year, Baxter is committing $200,000 to create the Baxter Nursing Scholars Award at Tennessee State University's (TSU) School of Nursing and

Baxter Expands Historically Black Colleges and Universities Partnerships, Funding Commitments to Further the Pipeline of Black Healthcare Professionals

Latest regulatory approval for Baxter's (BAX) Novum IQ SYR is expected to provide safe and accurate infusions for vulnerable patients.

Baxter (BAX) Novum IQ SYR's FDA Clearance Boosts Patient Care

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its new Novum IQ syringe infusion pump (SYR) with Dose IQ Safety Software, representing Baxter's latest developments for infusion therapy. The Novum IQ SYR has the capability to fully integrate with hospital electronic medical records (EMRs) through Baxter's IQ Enterprise Connectivity Suite.

Baxter Announces U.S. FDA Clearance of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 10:25 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through February 23, 2023. About Baxter Every day, millions of patients and caregivers rely on Baxter'

Baxter to Present at the 2022 Wells Fargo Healthcare Conference

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 10:35 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through March 13, 2023. About Baxter Every day, millions of patients and caregivers

Baxter to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Baxter boasts a broad portfolio of medically necessary products and therapies, and its brand strength is a key advantage. The company's products can be found in just about any healthcare facility from hospitals to nursing homes and beyond in over 100 countries.

Baxter's Shares Are Starting To Look Cheap

Baxter's (BAX) second-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.

Baxter (BAX) Q2 Earnings Miss Estimates, Hilrom Adds $715 M

Investors weren't happy with the company's Q2 update.

Why Baxter International Stock Is Tumbling Today

Baxter International Inc. (NYSE:BAX ) Q2 2022 Results Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Clare Trachtman - Vice President, Investor Relations José Almeida - Chairman, President and Chief Executive Officer James Saccaro - ​Executive Vice President and Chief Financial Officer Conference Call Participants Robbie Marcus – J.P. Morgan Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Travis Steed - Bank of America Securities Joanne Wuensch - Citigroup Larry Biegelsen - Wells Fargo Joshua Jennings - Cowen and Company Operator Good morning, ladies and gentlemen, and welcome to Baxter International's Second Quarter 2022 Earnings Conference Call.

Baxter International Inc. (BAX) CEO José Almeida on Q2 2022 Results - Earnings Call Transcript

Baxter (BAX) delivered earnings and revenue surprises of -1.14% and 3.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2022. “Baxter's diverse, durable portfolio of essential healthcare products powers our business, even amid unprecedented macroeconomic headwinds,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “While we continue to navigate a dynamic near-term landscape, our recent combination with Hillrom is fueling the next phase of ou

Baxter Reports Second-Quarter 2022 Results

Baxter's (BAX) second-quarter results are likely to reflect growth in its Medication Delivery and BioPharma Solutions businesses. Hillrom's products are likely to have boosted sales

Baxter (BAX) to Report Q2 Earnings: What's in the Offing?

Cummins

Marsh & McLennan

Realty Income Corp

Phillips 66

Daily Dividend Report: Cummins, Marsh McLennan, Baxter International, Realty Income, Phillips 66

DEERFIELD, Ill.--(BUSINESS WIRE)---- $BAX--Baxter International Inc. (NYSE:BAX), a global medtech leader, today released its 2021 Corporate Responsibility Report, demonstrating how the company is progressing toward its 2030 Corporate Responsibility Commitment and Goals. The report highlights the continued progress Baxter has made to advance environmental, social and governance (ESG) performance across its operations and philanthropic programs. “Baxter's unwavering dedication to responsible corporate cit

Baxter Details Progress Toward Environmental, Social and Governance (ESG) Priorities in Annual Corporate Responsibility Report

Alnylam Pharmaceuticals

Biogen

Boston Scientific

Cardinal Health

Gilead Sciences

Johnson & Johnson

Karuna Therapeutics Inc

Medtronic

Mirati Therapeutics

Natera

Roche Holding AG

Stryker

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

If you have the discipline to think long-term as an investor, this is the time to take advantage of the steep discounts on great biotechnology companies.

News for Baxter Stock (BAX)